SCHEMBL30765633

SCHEMBL30765633

C[C@@H](N)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
NPC1 O15118 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.55
RAB9A P51151 3/20 0.55
AHR P35869 2/20 0.46
CYP1A2 P05177 3/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2D6 P10635 1/20 0.45
TNKS O95271 1/20 0.42
PARP1 P09874 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
MAOA P21397 2/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765533 1.00 MAPT (0.55) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL30765515 1.00 MAPT (0.55) MAPTNPC1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL30765518 0.98 MAPT (0.53) MAPTNPC1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL31558469 0.98 MAPT (0.53) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL30765796 0.89 MEN1 (0.53) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL30765598 0.86 MAPT (0.51) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL1102393 0.85 MEN1 (0.53) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL7246583 0.85 MAPT (0.58) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL22787856 0.82 MAPT (0.50) MAPTNPC1SMN1; SMN2MEN1KMT2A
SCHEMBL25144257 0.81 MAPT (0.49) MAPTNPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed